Related references
Note: Only part of the references are listed.Phase I/II study of MDV3100 in patients (pts) with progressive castration-resistant prostate cancer (CRPC)
H. I. Scher et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
An F876L Mutation in Androgen Receptor Confers Genetic and Phenotypic Resistance to MDV3100 (Enzalutamide)
Manav Korpal et al.
CANCER DISCOVERY (2013)
A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509
James D. Joseph et al.
CANCER DISCOVERY (2013)
Putting the brakes on continued androgen receptor signaling in castration-resistant prostate cancer
Andrew Eichholz et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2012)
Synthesis and in vitro characterization of ionone-based chalcones as novel antiandrogens effective against multiple clinically relevant androgen receptor mutants
Jinming Zhou et al.
INVESTIGATIONAL NEW DRUGS (2010)
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study
Howard I. Scher et al.
LANCET (2010)
NF-κB Regulates Androgen Receptor Expression and Prostate Cancer Growth
Liying Zhang et al.
AMERICAN JOURNAL OF PATHOLOGY (2009)
NFκB signaling in carcinogenesis and as a potential molecular target for cancer therapy
Han-Ming Shen et al.
APOPTOSIS (2009)
Syntheses and potential anti-prostate cancer activities of ionone-based chalcones
Jinming Zhou et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2009)
CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer
Je Ang et al.
BRITISH JOURNAL OF CANCER (2009)
Development of Androgen Receptor Antagonists with Promising Activity in Castration-Resistant Prostate Cancer
Howard C. Shen et al.
CANCER CELL (2009)
Steroid Hormone Receptors in Prostate Cancer: A Hard Habit to Break?
Gerhardt Attard et al.
CANCER CELL (2009)
Antitumor Activity with CYP17 Blockade Indicates That Castration-Resistant Prostate Cancer Frequently Remains Hormone Driven
Gerhardt Attard et al.
CANCER RESEARCH (2009)
Interleukin-6 Regulates Androgen Synthesis in Prostate Cancer Cells
Jae Yeon Chun et al.
CLINICAL CANCER RESEARCH (2009)
Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor
Kamilla Malinowska et al.
ENDOCRINE-RELATED CANCER (2009)
Design and Synthesis of Androgen Receptor Antagonists with Bulky Side Chains for Overcoming Antiandrogen Resistance
Jinming Zhou et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
Chris Tran et al.
SCIENCE (2009)
The nuclear factor-κB pathway controls the progression of prostate cancer to androgen-independent growth
Ren Jie Jin et al.
CANCER RESEARCH (2008)
Advances in targeting IKK and IKK-related kinases for cancer therapy
Dung-Fang Lee et al.
CLINICAL CANCER RESEARCH (2008)
Androgen receptor: role and novel therapeutic prospects in prostate cancer
Mary-Ellen Taplin
EXPERT REVIEW OF ANTICANCER THERAPY (2008)
Integrative Microarray analysis of pathways dysregulated in metastatic prostate cancer
Sunita R. Setlur et al.
CANCER RESEARCH (2007)
Effects of steroidal and non-steroidal antiandrogens on wild-type and mutant androgen receptors
Masayasu Urushibara et al.
PROSTATE (2007)
Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient
T Yoshida et al.
CANCER RESEARCH (2005)
The IKKNF-kappa B system: A treasure trove for drug development
M Karin et al.
NATURE REVIEWS DRUG DISCOVERY (2004)
Molecular determinants of resistance to antiandrogen therapy
CD Chen et al.
NATURE MEDICINE (2004)
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
DP Petrylak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
IF Tannock et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Androgen receptor mutations in androgen-in dependent prostate cancer: Cancer and Leukemia Group B Study 9663
ME Taplin et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Broadened ligand responsiveness of androgen receptor mutants obtained by random amino acid substitution of H874 and mutation hot spot T877 in prostate cancer
K Steketee et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Share Paper
